Mesenchymal stem cells (MSCs) are proposed to be useful in cartilage regenerative medicine, however, canine MSCs have been reported to show poor chondrogenic capacity. Therefore, optimal conditions for chondrogenic differentiation should be determined by mimicking the developmental process. We have previously established novel and superior canine MSCs named bone marrow peri-adipocyte cells (BM-PACs) and the objective of this study was to evaluate the effects of growth factors required for in vivo chondrogenesis using canine BM-PACs. Spheroids of BM-PACs were cultured in chondrogenic medium containing 10 ng/ml transforming growth factor-β1 (TGF-β1) with or without 100 ng/ml bone morphogenetic protein-2 (BMP-2), 100 ng/ml growth differentiation factor-5 (GDF-5) or 100 ng/ml insulin-like growth factor-1 (IGF-1). Chondrogenic differentiation was evaluated by the quantification of glycosaminoglycan and Safranin O staining for proteoglycan production. The expression of cartilage matrix or hypertrophic gene/protein was also evaluated by qPCR and immunohistochemistry. Spheroids in all groups were strongly stained with Safranin O. Although BMP-2 significantly increased glycosaminoglycan production, Safranin O-negative outer layer was formed and the mRNA expression of COL10 relating to cartilage hypertrophy was also significantly upregulated (P<0.05). GDF-5 promoted the production of glycosaminoglycan and type II collagen without increasing COL10 mRNA expression. The supplementation of IGF-1 did not significantly affect cartilaginous and hypertrophic differentiation. Our results indicate that GDF-5 is a useful growth factor for the generation of articular cartilage from canine MSCs.
Mesenchymal stem cells (MSCs) are proposed to be useful in cartilage regenerative medicine, however, canine MSCs have been reported to show poor chondrogenic capacity. Therefore, optimal conditions for chondrogenic differentiation should be determined by mimicking the developmental process. We have previously established novel and superior canine MSCs named bone marrow peri-adipocyte cells (BM-PACs) and the objective of this study was to evaluate the effects of growth factors required for in vivo chondrogenesis using canine BM-PACs. Spheroids of BM-PACs were cultured in chondrogenic medium containing 10 ng/ml transforming growth factor-β1 (TGF-β1) with or without 100 ng/ml bone morphogenetic protein-2 (BMP-2), 100 ng/ml growth differentiation factor-5 (GDF-5) or 100 ng/ml insulin-like growth factor-1 (IGF-1). Chondrogenic differentiation was evaluated by the quantification of glycosaminoglycan and Safranin O staining for proteoglycan production. The expression of cartilage matrix or hypertrophic gene/protein was also evaluated by qPCR and immunohistochemistry. Spheroids in all groups were strongly stained with Safranin O. Although BMP-2 significantly increased glycosaminoglycan production, Safranin O-negative outer layer was formed and the mRNA expression of COL10 relating to cartilage hypertrophy was also significantly upregulated (P<0.05). GDF-5 promoted the production of glycosaminoglycan and type II collagen without increasing COL10 mRNA expression. The supplementation of IGF-1 did not significantly affect cartilaginous and hypertrophic differentiation. Our results indicate that GDF-5 is a useful growth factor for the generation of articular cartilage from canine MSCs.
Articular cartilage contains abundant extracellular matrix (ECM), rich in glycosaminoglycans
(GAGs), proteoglycans, and type II collagen [3].
Articular cartilage injury is common in dogs, because young and old dogs often suffer from
joint diseases such as hip dysplasia, osteochondritis dissecans, and rupture of the cranial
cruciate ligament [24, 32, 47]. Dogs suffering from pain or lameness
caused by injured cartilages are traditionally treated with administration of analgesics such
as non-steroidal anti-inflammatory drugs, or debridement of necrotic tissues including
subchondral bone. However, regardless of these treatments, severely injured cartilage never
regenerates because of blood supply privation in the articular cartilage, which ultimately
results in secondary osteoarthritis and causes progressive joint degeneration and persistent
joint pain [34]. Therefore, a new and radical
therapeutic strategy to regenerate cartilage tissue is required.Mesenchymal stem cells (MSCs) are immature cells that can be easily isolated from somatic
tissues such as bone marrow, adipose, and synovial tissues [21]. MSCs have high proliferative capability and multipotency to differentiate into
osteoblasts, adipocytes and chondrocytes [5]. MSCs are
also known to differentiate into chondrocytes in aggregation culture, mimicking the process of
cartilage development. Therefore, MSCs hold promise for practical application to cartilage
regenerative medicine in dogs [18, 46]. However, previous studies in canine MSCs have failed
to demonstrate sufficient chondrogenic potential with abundant ECMs such as proteoglycans and
type II collagen [4, 17, 20, 30, 31]. We previously established novel
methods of culturing canine MSCs named bone marrow peri-adipocyte cells (BM-PACs), isolated
from cells adhering to mature adipocytes in bone marrow [22]. BM-PACs showed superior proliferative capability and multipotency compared to
those of conventional bone marrow-derived MSCs and can be a promising cell source for
regenerative therapy in dogs. Although the potential of robust chondrogenesis is still
unclear, the investigation of optimal conditions for the chondrogenic differentiation using
canine BM-PACs is useful to mimic the chondrogenic process of MSCs.In the early stage of cartilage development, condensed mesenchymal cells rapidly proliferate
and differentiate into chondrocytes, which subsequently mature into articular chondrocytes
[15]. However, a portion of chondrocytes separately
undergo hypertrophic differentiation with losing their cartilaginous phenotype, ultimately
inducing vascularization and bone formation [15]. To
effectively maximize the chondrogenic potential of canine MSCs, it is necessary to explore the
chondrogenic conditions that mimic the environment of cartilage development to avoid
hypertrophic and osteogenic differentiation.During in vivo cartilage development, many growth factors controlling the
formation of cartilage and bone are reported to be secreted, such as transforming growth
factor-β1 (TGF-β1), bone morphogenetic protein-2 (BMP-2), growth differentiation factor-5
(GDF-5), and insulin-like growth factor-1 (IGF-1) [12].
TGF-β1 is a key regulator of cartilage development from early mesenchymal condensation to
terminal differentiation [45]. In 1998, Johnstone
et al. first reported that TGF-β1 was essential for in
vitro cartilage generation from rabbit MSCs in a three-dimensional culture system
[18]. Both BMP-2 and GDF-5 belong to the TGF-β
superfamily. Although BMP-2 stimulates the proliferation and matrix production of
chondroprogenitors in early chondrogenesis, it also strongly stimulates hypertrophic
differentiation and osteogenesis [44]. Interestingly,
GDF-5, also known as cartilage-derived morphogenetic protein-1, induces the formation of
mesenchymal condensation [11]. In later development
stages, GDF-5 is reported to be expressed in the joint interzone and control joint formation
[42]. IGF-1 is a regulator of proliferation and
differentiation in many types of cells and is known to promote cell division of chondrocytes
at various stages [27]. Therefore, these growth factors
have been reported to promote in vitro chondrogenic differentiation of human
MSCs in combination with TGF-β1 [9, 10, 29, 33, 38], and similar
chondrogenic effects can be expected in canine MSCs. Hence, more effective chondrogenic
conditions can be established to generate high-quality cartilages by evaluating the effect of
these growth factors on canine MSC chondrogenesis.The purpose of this study was to investigate the optimal growth factor conditions for canine
MSCs to enhance the synthesis of articular cartilage ECMs without inducing hypertrophic
differentiation. We supplemented BMP-2, GDF-5, and IGF-1 to chondrogenic induction medium
containing TGF-β1 and evaluated their effects on the chondrogenesis of BM-PACs.
MATERIALS AND METHODS
Animals
Bone marrow samples were harvested from six healthy young beagles (3 males and 3 females,
aged between 8 and 13 months) under general anesthesia, induced with propofol, and
maintained with isoflurane (2.0%) in oxygen. All animal experiments were approved by the
Animal Care Committee of the Graduate School of Agricultural and Life Sciences at the
University of Tokyo (the approval number P15-30).
Isolation and expansion of canine BM-PACs
Canine BM-PACs were cultured according to a previously described method [22] with modifications in the composition of the growth
medium after ceiling culture. Briefly, bone marrow aspirated from the proximal humerus was
subjected to density gradient centrifugation with Ficoll-Paque (GE Healthcare, Little
Chalfont, U.K.). After centrifugation, the top adipose layer containing mature adipocytes
was transferred into a new tube and washed twice with Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, U.S.A.) supplemented with 10% fetal bovine serum (FBS;
Invitrogen) and 1% penicillin-streptomycin/amphotericin-B (Wako, Tokyo, Japan). The mature
adipocytes, to which BM-PACs adhered, were then placed in 25-cm2 flasks
completely filled with DMEM supplemented with 20% FBS and 1% antibiotics and subjected to
ceiling culture at 37°C in a humidified atmosphere containing 5% CO2. The
ceiling culture was maintained for 5–7 days without replacing the medium until the cells
reached 100% confluence. The confluent cells were detached with 0.25% trypsin/1 mM
ethylenediaminetetraacetic acid solution (Wako) and passaged at a density of 1 ×
104 cells/cm2 in growth medium consisting of DMEM, 10% FBS, 1%
antibiotics, and 10 ng/ml human recombinant basic
fibroblast growth factor (bFGF; Peprotech, Rocky Hill, NJ, U.S.A.).
Chondrogenic differentiation
Cells at passage 1 were seeded in low-adhesion 96-multiwell plates (Sumitomo Bakelite,
Tokyo) at a density of 3 × 104 cells/well to form spheroids. For chondrogenic
differentiation, spheroids were cultured in 200 µl of chondrogenic
induction medium consisting of DMEM, 4.5 mg/ml D-(+)-glucose (Sigma, St.
Louis, MO, U.S.A.), 1% ITS liquid media supplement (Sigma), 1% linoleic acid-albumin from
bovine serum albumin (Sigma), 50 µg/ml ascorbic
acid-2-phosphate (Sigma), 0.1 µM dexamethasone (Sigma), 40
µg/ml L-proline (Peptide Institute Inc., Osaka,
Japan), and 10 ng/ml recombinant human TGF-β1
(Peprotech). To investigate the effect of growth factors on chondrogenesis, 100
ng/ml human recombinant BMP-2 (Shenandoah
Biotechnology, Warwick, PA, U.S.A.), 100 ng/ml human
recombinant GDF-5 (ProSpec-Tany TechnoGene, Rehovot, Israel), or 100
ng/ml human recombinant IGF-1 (R&D Systems,
Minneapolis, MN, U.S.A.) was added to chondrogenic induction medium. Groups cultured with
BMP-2, GDF-5, and IGF-1 were referred to as T+B, T+G, and T+I, respectively. As a control,
spheroids were cultured in chondrogenic induction medium (T group). Spheroids were
cultured for 14 days at 37°C in an atmosphere containing 5% CO2 and the medium
was changed twice a week. The diameter of the spheroids was continuously measured by
microscopic observation.
Biochemical analysis
For quantification of GAGs and DNA, spheroids were collected 7 and 14 days after
chondrogenic induction and digested with 100 µg/ml
papain at 65°C for 4 hr. DNA content was measured by Hoechst 33258 dye (Dojindo Molecular
Technologies, Kumamoto, Japan). Fluorescence intensity was measured using the multilabel
counter ARVO MX (Perkin Elmer, Waltham, MA, U.S.A.) at an excitation wavelength of 355 nm
and an emission wavelength of 460 nm. Calf thymus DNA (Sigma) was used for the generation
of a standard curve. GAG content was then quantified by a Blyscan Kit (Biocolor, Westbury,
NY, U.S.A.) according to the manufacturer’s instructions. The optical density was measured
at 630 nm and total GAG content was calculated. For comparison of GAG production, GAG
content was normalized to DNA content (GAG/DNA). Each experiment was performed in
duplicate.
Histology and immunohistochemistry
Spheroids were fixed with 10% formalin neutral buffer solution (Wako), dehydrated, and
embedded in paraffin. Specimens were cut into 4-µm sections. Safranin O
staining was performed for the detection of proteoglycans. For immunohistochemistry of
type II, I, and X collagen, sections were treated with 50
µg/ml proteinase K (Promega, Madison, WI, U.S.A.) for
10 min at room temperature. For type II collagen, an additional antigen retrieval step was
carried out using 25 mg/ml hyaluronidase (Sigma) for 2 hr at 37°C.
Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30
min. After washing with Tris-buffered saline containing 0.1% Tween-20 (TBS-T), the
sections were blocked with TBS-T containing 10% normal goat serum (Sigma) for 30 min at
room temperature, and then incubated with rabbit anti-type II collagen antibody (1:200;
LSL, Tokyo, Japan), mouse anti-type I collagen antibody (1:1,000; Abcam, Cambridge, U.K.),
and mouse anti-type X collagen antibody (1:1,000; Sigma) at 4°C overnight. The slides were
washed with TBS-T and incubated with horseradish peroxidase-labeled polymer (Dako, Tokyo,
Japan) for 1 hr at room temperature. Finally, diaminobenzidine substrate (Dako) was placed
on the slides and all slides were counterstained with hematoxylin.
Real-time polymerase chain reaction (RT-PCR)
After 14 days of chondrogenic induction, the spheroids were homogenized in TRI Reagent
(Cosmo Bio, Tokyo, Japan) and total RNA was obtained. Complementary DNA was synthesized
with ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan). The
real-time fluorescence intensity of the SYBR Green dye (Thunderbird SYBR qPCR Mix, Toyobo)
was monitored with the Step One Plus Real-Time PCR system (Applied Biosystems, Foster
City, CA, U.S.A.). The mRNA expression of chondrogenic marker genes (SOX9, ACAN, and
COL2), the fibrocartilage marker gene COL1, and the hypertrophic chondrocyte marker gene
COL10 was evaluated. The primers used for PCR are listed in Table 1. All reactions were performed as follows: 95°C for 10 min, 40 cycles at 95°C
for 15 sec and 60°C for 1 min. The mRNA expression levels were normalized to that of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In addition, the ratio of COL2 to COL1
(COL2/COL1) was calculated to evaluate differentiation into hyaline cartilage. Each
experiment was performed in triplicate.
Table 1.
Primers used for semi-quantitative RT-PCR
Genes
Sequence (5′-3′)
SOX9
Forward
AAGCTCTGGAGGCTGCTGAA
Reverse
ACTTGTAATCCGGGTGGTCTTT
ACAN
Forward
CCTACGATGTCTACTGCTATGTGG
Reverse
CAGGGTGGCGTTATGAGATTC
COL2
Forward
CCCGAACCCACAAACAACA
Reverse
AGCCATTCAGTGCAGAGCC
COL1
Forward
GTAGACACCACCCTCAAGAGC
Reverse
TTCCAGTCGGAGTGGCACATC
COL10
Forward
TTCCAGGACAGCCAGGCATCA
Reverse
TTCCCAGTGCCTTCTGGTCC
GAPDH
Forward
TGACACCCACTCTTCCACCTTC
Reverse
CGGTTGCTGTAGCCAAATTCA
Statistical analysis
All data were expressed as the mean ± standard deviation. Comparisons were made using
one-way analysis of variance followed by Tukey’s multiple comparisons test between
multiple unpaired groups. Statistical significance was defined as
P<0.05. All statistical analyses were performed with EZR (Saitama
Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user
interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [19].
RESULTS
Spheroid diameter
Spheroids in all groups maintained their size from day 7 through to day 14, and the
spheroid diameter in the T+B group was significantly larger than that in the other groups
(P<0.05, Fig. 1).
Fig. 1.
The diameter of spheroids after 7 and 14 days of chondrogenic differentiation under
the presence of bone morphogenetic protein-2(BMP-2) (B), growth differentiation factor-5 (GDF-5) (G), or
insulin-like growth factor-1 (IGF-1) (I) combined with transforming growth factor-β1
(TGF-β1) (T). Spheroid diameter in the T+B group was significantly larger than those
in the other groups. Groups indicated by different letters show significant
differences (P<0.05).
The diameter of spheroids after 7 and 14 days of chondrogenic differentiation under
the presence of bone morphogenetic protein-2(BMP-2) (B), growth differentiation factor-5 (GDF-5) (G), or
insulin-like growth factor-1 (IGF-1) (I) combined with transforming growth factor-β1
(TGF-β1) (T). Spheroid diameter in the T+B group was significantly larger than those
in the other groups. Groups indicated by different letters show significant
differences (P<0.05).
Quantification of DNA and GAGs
Chondrogenically induced spheroids were digested and the DNA and GAG contents in the
spheroids were measured. The DNA content in the spheroids in the T+B group was
significantly higher than those in the other groups after 7 and 14 days of chondrogenic
induction (P<0.05, Fig.
2A). The GAG content was significantly higher in the T+B group than those in the T and
T+I groups (P<0.05, Fig.
2B). Treatment with GDF-5 increased GAG deposition, but not significantly. To
correct for cell number in the spheroids, GAG content was divided by DNA content. After 7
days of chondrogenic induction, there was no significant differences in GAG/DNA among the
four groups. However, GAG/DNA was significantly higher in the T+B and T+G groups than
those in the other groups on day 14 (Fig.
2C).
Fig. 2.
Quantification of DNA and glycosaminoglycan (GAG) content after 7 and 14 days of
chondrogenic induction under the presence of bone morphogenetic protein-2 (BMP-2)
(B), growth differentiation factor-5 (GDF-5) (G), or insulin-like growth factor-1
(IGF-1) (I) combined with transforming growth factor-β1 (TGF-β1) (T). (A) The DNA
content of spheroids in the T+B group was significantly higher than those in the
other groups. (B) Total GAG content in spheroids was significantly higher in the T+B
group than in the other groups. (C) To evaluate the efficiency of GAG production,
the ratio of GAG to DNA was calculated. GAG/DNA was significantly increased in the
T+B and T+G groups on day 14. Groups indicated by different letters show significant
differences (P<0.05).
Quantification of DNA and glycosaminoglycan (GAG) content after 7 and 14 days of
chondrogenic induction under the presence of bone morphogenetic protein-2 (BMP-2)
(B), growth differentiation factor-5 (GDF-5) (G), or insulin-like growth factor-1
(IGF-1) (I) combined with transforming growth factor-β1 (TGF-β1) (T). (A) The DNA
content of spheroids in the T+B group was significantly higher than those in the
other groups. (B) Total GAG content in spheroids was significantly higher in the T+B
group than in the other groups. (C) To evaluate the efficiency of GAG production,
the ratio of GAG to DNA was calculated. GAG/DNA was significantly increased in the
T+B and T+G groups on day 14. Groups indicated by different letters show significant
differences (P<0.05).
Histological evaluation
After 14 days of chondrogenic induction, Safranin O staining and immunohistochemistry for
type II, I, and X collagen were performed to evaluate the deposition of cartilage matrix
(Fig. 3). Spheroids in all groups were strongly stained with Safranin O, and the center of
the spheroids revealed stronger staining. However, there was no apparent difference in the
intensity of Safranin O staining among all groups. In the T+B group, a thicker Safranin
O-negative outer layer was formed and consisted of fibroblast-like cells.
Immunohistochemistry revealed that all spheroids expressed type II collagen, especially in
the center. The outer fibroblastic layer of the spheroids in the T+B group was slightly
positive for type II collagen immunostaining. In the T+G group, the spheroids showed
higher expression of type II collagen. Type I collagen, which is a marker of
fibrocartilages, was apparently detected on the outer surface of the spheroids in all
groups. Type X collagen, a marker of hypertrophic chondrocytes, was not detected in any
group.
Fig. 3.
Safranin O staining and immunohistochemistry for type II, I, and X collagen after
14 days of chondrogenic induction under the presence of bone morphogenetic protein-2
(BMP-2) (B), growth differentiation factor-5 (GDF-5) (G), or insulin-like growth
factor-1 (IGF-1) (I) combined with transforming growth factor-β1 (TGF-β1) (T).
Spheroids in all groups were strongly stained with Safranin O, and stronger staining
was observed in the center of the spheroids. In the T+B group, a Safranin O-negative
outer layer was formed. All spheroids expressed type II collagen, especially in the
center of the spheroids, and the T+G group showed higher expression of type II
collagen. The outer fibroblastic layer of the spheroids in the T+B group showed
slight expression of type II collagen. Type I collagen was apparently detected on
the outer surface of spheroids in all groups. No type X collagen expression was
detected in any group. All scale bars indicate 100 µm.
Safranin O staining and immunohistochemistry for type II, I, and X collagen after
14 days of chondrogenic induction under the presence of bone morphogenetic protein-2
(BMP-2) (B), growth differentiation factor-5 (GDF-5) (G), or insulin-like growth
factor-1 (IGF-1) (I) combined with transforming growth factor-β1 (TGF-β1) (T).
Spheroids in all groups were strongly stained with Safranin O, and stronger staining
was observed in the center of the spheroids. In the T+B group, a Safranin O-negative
outer layer was formed. All spheroids expressed type II collagen, especially in the
center of the spheroids, and the T+G group showed higher expression of type II
collagen. The outer fibroblastic layer of the spheroids in the T+B group showed
slight expression of type II collagen. Type I collagen was apparently detected on
the outer surface of spheroids in all groups. No type X collagen expression was
detected in any group. All scale bars indicate 100 µm.
Gene expression analysis
To assess the expression of chondrogenic genes, cultured spheroids were collected on day
14 (Fig. 4). The expression of chondrogenic genes (SOX9, ACAN, and COL2) and the
fibrocartilage gene COL1 did not show remarkable differences in the different chondrogenic
media. The ratio of COL2 to COL1 (COL2/COL1) was higher in the T+G group, but not
significantly (P=0.14). Additionally, BMP-2 treatment significantly
increased the expression of COL10, a hypertrophic gene (P<0.05). The
expression of COL10 was upregulated in the T+G group, but not significantly.
Fig. 4.
Gene expression analysis after 14 days of chondrogenic induction under the presence
of bone morphogenetic protein-2 (BMP-2) (B), growth differentiation factor-5 (GDF-5)
(G), or insulin-like growth factor-1 (IGF-1) (I) combined with transforming growth
factor-β1 (TGF-β1) (T). There was no apparent change in the mRNA expression of SOX9,
ACAN, COL2, and COL1. The ratio of COL2 to COL1 (COL2/COL1) was higher in the T+G
group, but not significantly. The expression of COL10 was significantly increased in
the T+B group. The expression of COL10 was upregulated in the T+G group, but not
significantly. Groups indicated by different letters show significant differences
(P<0.05).
Gene expression analysis after 14 days of chondrogenic induction under the presence
of bone morphogenetic protein-2 (BMP-2) (B), growth differentiation factor-5 (GDF-5)
(G), or insulin-like growth factor-1 (IGF-1) (I) combined with transforming growth
factor-β1 (TGF-β1) (T). There was no apparent change in the mRNA expression of SOX9,
ACAN, COL2, and COL1. The ratio of COL2 to COL1 (COL2/COL1) was higher in the T+G
group, but not significantly. The expression of COL10 was significantly increased in
the T+B group. The expression of COL10 was upregulated in the T+G group, but not
significantly. Groups indicated by different letters show significant differences
(P<0.05).
DISCUSSION
Spheroids of BM-PACs were cultured in chondrogenic induction medium supplemented with
BMP-2, GDF-5, or IGF-1 to evaluate the potential of these growth factors for enhancing
chondrogenesis. BMP-2 increased the spheroid diameter, DNA content, and GAG/DNA ratio. These
results suggested that BMP-2 enhanced the proliferation of BM-PACs as well as GAG production
per cell. Consistent with our results, it has been previously reported that BMP-2 promotes
cell proliferation and cartilaginous matrix production during chondrogenesis of human MSCs
[26, 36,
38, 39]. In
contrast, supplementation of GDF-5 increased only GAG/DNA. IGF-1 had no significant effect
on GAG or DNA content. Based on the results in this study, it is proposed that unlike BMP-2,
GDF-5 stimulates only GAG production in chondrogenically differentiated cells, without
promoting growth activity.As shown in the histological evaluation, all spheroids demonstrated evidence of
chondrogenic differentiation with sufficient expression of proteoglycans and type II
collagen. However, a difference was observed in the outer layer of the spheroids. The outer
layer of the spheroids in the T+B group showed negative Safranin O staining and slight
immunostaining for type II collagen. While BMP-2 is known to be a strong inducer of
chondrogenesis, it has also been demonstrated that in vitro osteogenic
differentiation of MSCs is promoted by BMP-2 treatment [43]. Cheng et al. have reported that forced expression of BMP-2
in rabbit MSCs induced in vivo ectopic bone tissue formation [7]. Furthermore, in this study, BMP-2 significantly
increased the mRNA expression of COL10. This result is consistent with a previous study,
which showed that the expression of type X collagen was upregulated by BMP-2 during
chondrogenesis of human bone marrow-derived MSCs and rabbit periosteal explants [6, 38]. Therefore,
it is suggested that cells in the outer layer of the spheroids were losing their
cartilaginous phenotype, and contributed to further endochondral ossification. Accordingly,
BMP-2 possibly induced hypertrophic differentiation during chondrogenesis of canine BM-PACs.
Nevertheless, immunohistochemistry revealed the absence of type X collagen expression in the
present study. Sekiya et al. demonstrated that the mRNA expression of COL10
was already increased before the histochemical detection of hypertrophy during in
vitro chondrogenesis of human MSCs [38].
Although there is a possibility that immunohistochemistry could not detect the slight
protein expression of type X collagen, the observation for a longer period should be
performed to evaluate hypertrophic differentiation. In contrast, GDF-5 increased the
expression of type II collagen and the index of hyaline cartilage genes (COL2/COL1) without
significantly upregulating COL10 mRNA expression. These results are in agreement with a
previous study by Ayerst et al., which demonstrated that the combination of
TGF-β1 and GDF-5 enhanced chondrogenic gene expression without stimulating type X collagen
expression during the chondrogenesis of human bone marrow-derived MSCs [1]. Although further studies are required to evaluate the
long-term effect of GDF-5 on hypertrophic differentiation, our results demonstrated that
GDF-5 promoted hyaline cartilage differentiation of canine BM-PACs without inducing
hypertrophy and could be useful for articular cartilage regeneration.Some studies have shown that IGF-1 has additive effects on TGF-β-induced human MSC
chondrogenesis through the regulation of proliferation, apoptosis, and cartilage matrix
production even under the presence of insulin [16,
33]. In this study, supplementation of IGF-1 at the
same concentration as these previous studies increased neither GAG production nor the
expression of hypertrophic genes in canine BM-PACs. IGF-1 is a polypeptide with a very
similar amino acid sequence to that of insulin and regulates cartilage homeostasis and ECM
synthesis via its receptor, IGF-1R [13, 35]. Longobardi et al. demonstrated the
chondroinductive effect of IGF-1 in mouse bone marrow-derived MSCs under the absence of
insulin because insulin has low binding affinity to IGF-1R [23]. Since it has been reported that canine MSCs react with recombinant humanIGF-1 at much lower concentration (2–5 ng/ml) [2, 37], there is a
possibility that the effect of IGF-1 was masked by the presence of insulin during
chondrogenic differentiation of canine BM-PACs. To clarify the effect of IGF-1 on canine MSC
chondrogenesis, chondrogenic assay at different concentrations of IGF-1 or under an
insulin-free condition should be demonstrated.The induction medium containing TGF-β1 alone successfully induced cartilaginous spheroids
with the expression of proteoglycans and type II collagen. In this study, we routinely
supplemented bFGF to the growth medium of BM-PACs before chondrogenic induction. bFGF, also
known as FGF-2, is a growth factor that stimulates cell division and vascularization [25]. Previous studies have indicated that bFGF
supplementation to growth medium enhanced the proliferation and chondrogenic potential of
human MSCs [8, 14, 28, 40]. Although the effect and underlying mechanism of bFGF preconditioning is
unclear in canine MSCs, it is suggested that bFGF contributed to the robust chondrogenesis
of canine BM-PACs.Despite the poor chondrogenic capacity of canine MSCs, so far, only a few studies have
investigated the effect of growth factors on canine MSC chondrogenesis [30, 41]. Russel
et al. observed no evidence of cartilage matrix deposition in canine
adipose tissue-derived MSCs, even when BMP-2 was added to chondrogenic induction medium
containing TGF-β3 [30]. Since this study is the first
report to evaluate the effect of GDF-5 and its chondrogenic effect was confirmed only in
BM-PACs, further studies should be conducted to elucidate whether GDF-5 promotes
chondrogenesis of other types of canine MSCs.In conclusion, BMP-2 stimulated cell proliferation and GAG production in spheroids of
canine MSCs during chondrogenic differentiation induced by TGF-β, but upregulation of the
type X collagen gene indicated that BMP-2 simultaneously promoted hypertrophic
differentiation. Moreover, the combination of TGF-β1 and GDF-5 increased the deposition of
glycosaminoglycan and tended to increase type II collagen expression without inducing
hypertrophic differentiation. These findings indicate that, when combined with TGF-β1, GDF-5
is more useful growth factor to allow in vitro articular cartilage
generation from canine MSCs compared with BMP-2 and IGF-1 and will accelerate research on
caninecartilage regeneration and disease treatment.